Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib + Letrozole in HR+ Metastatic Breast Cancer
NCT00708214Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2007
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in breast cancer, sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Progression Free Participants at 16 weeks. Started Jan 2007; status: completed.
02
Drugs
afatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00708214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00708214.